HOME
ABOUT
History And Growth
Marketing, Sales & Distribution
Board of Directors
Management Team
Our People
Corporate Social Responsibility (CSR)
Certifications
Photo Gallery
PRODUCTS
By Trade Name
By Generic Name
By Therapeutic Class
Product Catalogue
FACILITIES
Quality Policy
Manufacturing Facility
Quality Assurance
HVAC system
Cephalosporin Unit
Wastewater Treatment
INVESTOR
NOTICE
Notice of BOM June 2024
Notice of BOM March 2024
Notice of the unclaimed dividend 2020
Notice_28th AGM 22-23
Notice_27th AGM 21-22
Notice_26th AGM 20-21
Notification for GIS 21-22
Notification for GIS 22-23
Notice-of-BOM-June-2023.
Notice-of-BOM-March-2023.
Notice-of-BOM-Dec.-2022.
Notice-of-BOM-Sep.-2022.
Notice-of-BOM-June-2022.
Notice-of-BOM-Dec.-2021.
Notice-of-BOM-Sept.-2021.
Notice-of-BOM-June-2021.
Notice-of-BOM-March-2021.
Notice-of-BOM-March-2020.
Proxy-Form
IPO
Utilization Report
Prospectus
TT clean rate
Annual Report & Audited Accounts
Annual-Audited-Financial-Statements 22-23
Annual-Audited-Financial-Statements 21-22
Annual-Audited-Financial-Statements 20-21
Annual-Audited-Financial-Statements 19-20
Annual-Audited-Financial-Statements 18-19
Half Yearly Reports
Quarterly Reports
Price Sensitive Information
PSI Year Ended 30 June, 2024
C G Compliance Status
C G Compliance Report 22-23
C G Compliance Report 21-22
C G Compliance Report 20-21
C G Compliance Report 19-20
C G Compliance Report 18-19
Code of Conduct
Unpaid/Unclaimed Dividend
Dividend Disbursement Policy
Dividend Compliance Report 2023
GLOBAL OPERATIONS
CONTACT
Contact Us
News Room
Career
Select Page
Home
/
By Therapeutic Class
/ Antiasthmatic
Antiasthmatic
Category:
By Therapeutic Class
Description
Description
Related products
Antiulcerant
Antimicrobial
Mycolytic expectorant
